Alexis Pinto - 25 Oct 2021 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role: Chief Legal Officer
Signature: /s/ Melissa B. Epperly, Attorney-in-Fact for Alexis Pinto
Issuer symbol: ZNTL
Transactions as of: 25 Oct 2021
Net transactions value: -$1,300,002
Form type: 4
Filing time: 27 Oct 2021, 20:13:13 UTC
Next filing: 14 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ZNTL	Common Stock	Options Exercise	$1,032,000	+30,000	+460%	$34.40	36,526	25 Oct 2021	Direct	F1, F2
transaction	ZNTL	Common Stock	Sale	$136,973	-1,800	-4.9%	$76.10	34,726	25 Oct 2021	Direct	F1, F3
transaction	ZNTL	Common Stock	Sale	$625,731	-8,098	-23%	$77.27	26,628	25 Oct 2021	Direct	F1, F4
transaction	ZNTL	Common Stock	Sale	$1,545,643	-19,802	-74%	$78.05	6,826	25 Oct 2021	Direct	F1, F5
transaction	ZNTL	Common Stock	Sale	$23,655	-300	-4.4%	$78.85	6,526	25 Oct 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ZNTL	Stock Option (Right to Buy)	Options Exercise	$0	-30,000	-11%	$0.000000	245,000	25 Oct 2021	Common Stock	30,000	$34.40	Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
F2	Includes 276 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2021.
F3	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.57 to $76.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.59 to $77.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5	The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.59 to $78.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6	The options vest and become exercisable as to 25% of the total number of shares underlying the option on August 31, 2021 and as to the remaining 75% in 36 substantially equal monthly installments thereafter.